Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
Volume: 384, Issue: 2, Pages: 105 - 116
Published: Jan 14, 2021
Abstract
The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is...
Paper Details
Title
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
Published Date
Jan 14, 2021
Volume
384
Issue
2
Pages
105 - 116
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History